Status:

COMPLETED

A Study of Effectiveness and Safety of Paliperidone Extended-release (ER) Tablets in the Prevention of Recurrence in Adult Patients With Schizophrenia.

Lead Sponsor:

Johnson & Johnson Pharmaceutical Research & Development, L.L.C.

Conditions:

Schizophrenia

Eligibility:

All Genders

18-65 years

Phase:

PHASE3

Brief Summary

The purpose of this study is to determine the efficacy (effectiveness) and safety of paliperidone ER compared with placebo in the prevention of recurrence of symptoms of schizophrenia.

Detailed Description

Paliperidone ER is currently being investigated as treatment for the acute symptoms of schizophrenia and also as maintenance treatment. This trial is designed to evaluate efficacy and safety of palipe...

Eligibility Criteria

Inclusion

  • DSM-IV diagnosis of schizophrenia at least 1 year before screening
  • experiencing an acute schizophrenic episode with a total PANSS score between 70 and 120
  • agree to be hospitalized for a minimum of 14 days at the start of the study
  • capable of administering study medication themselves or have assistance with study medication administration consistently available throughout the study
  • resided at the same address continuously for at least 30 days prior to screening
  • able and willing to fill out self administered questionnaires
  • washout of antiparkinsonian medications, beta-blockers
  • antiepileptics, lithium 3 days prior to the start of the run-in phase

Exclusion

  • DSM-IV Axis I diagnosis other than schizophrenia
  • DSM-IV diagnosis of substance dependence within 6 months prior to screening (nicotine and caffeine dependence are not exclusionary)
  • preexisting severe gastrointestinal narrowing (pathologic or iatrogenic)
  • injection of a depot antipsychotic within 120 days before screening, or use of paliperidone palmitate within 10 months before screening
  • previous history of lack of response to risperidone when acutely psychotic
  • history of neuroleptic malignant syndrome
  • significant risk of suicidal or violent behavior

Key Trial Info

Start Date :

March 1 2004

Trial Type :

INTERVENTIONAL

Allocation :

ACTUAL

End Date :

August 1 2005

Estimated Enrollment :

111 Patients enrolled

Trial Details

Trial ID

NCT00086320

Start Date

March 1 2004

End Date

August 1 2005

Last Update

June 8 2011

Active Locations (0)

Enter a location and click search to find clinical trials sorted by distance.

Page 1 of 0 (0 locations)

No Results Found

We couldn’t find results for the location/zipcode entered or within the selected range. Please check your input or adjust your search.

A Study of Effectiveness and Safety of Paliperidone Extended-release (ER) Tablets in the Prevention of Recurrence in Adult Patients With Schizophrenia. | DecenTrialz